Cardiac muscle injury biomarker normalization

"Cardiac muscle injury biomarker normalization" refers to the clinical process of monitoring the levels of laboratory markers—including cardiac troponins (I and T), creatine kinase-MB (CK-MB), myoglobin, and natriuretic peptides—in blood as they return to normal after heart muscle injury such as myocardial infarction or cardiac surgery. These biomarkers rise upon cardiac injury and their normalization helps clinicians understand the extent and resolution of the injury. This phrase does not refer to a therapeutic target, protein, enzyme, or receptor, but rather to the laboratory observation and assessment of these values returning to baseline. Troponin I and T are currently the most specific and sensitive of these markers. Monitoring their normalization is essential for diagnosis, prognosis, and management of acute cardiovascular events, but there is no discrete 'molecular target' by this name.